SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

META is trending downwards following news of a planned bond sale to fund AI investments, sparking concerns about increased spending and potential impact on shareholder value. The community is debating whether the dip presents a buying opportunity, considering the company's fundamentals and long-term growth potential amid the AI push. Some investors are drawing comparisons to past overspending concerns while others see it as a strategic move for future growth.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. It provides online news services where users can select and rank web content. The firm also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit's stock is trending as investors anticipate upcoming earnings, with the community closely watching key metrics like user growth and advertising revenue. Bullish sentiment is fueled by analysts setting higher price targets and highlighting potential from AI and data licensing deals. Short interest is also a key factor being watched.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is trending as the community rallies behind the OG meme, fueled by a desire to reclaim internet culture. Discussions center on achieving the #1 spot and bringing back the spirit of the 2021 meme era. The community emphasizes belief, teamwork, and rejecting traditional financial analysis in favor of cultural relevance.

Cambium Networks Corp. is a holding company, which engages in the provision of wireless broadband networking infrastructure solutions for network operators. Its products include point-to-point, enterprise Wi-Fi and switching, CCTV, software, and point-to multipoint. The company was founded in 2011 and is headquartered in Hoffman Estates, IL.

Cambium Networks Corp

CMBM is trending due to excitement around its integration with Starlink, with retail traders discussing a potential short squeeze and high trading volume. Community members are debating resistance levels and potential price targets, while also weighing the company's fundamentals and potential for further gains. The stock's volatile price action and significant overnight gains have fueled speculation about its short-term trajectory.

Chipotle Mexican Grill, Inc. engages in the business of developing and operating restaurants that serve a relevant menu of burritos, burrito bowls, quesadillas, tacos, and salads made using fresh, high-quality ingredients. The company was founded by Steve Ells in 1993 and is headquartered in Newport Beach, CA.

Chipotle Mexican Grill

Chipotle ($CMG) is trending due to a significant drop following a lowered sales outlook, sparking discussions about consumer spending and the company's value proposition. Community members are debating whether the dip is a buying opportunity or a sign of deeper issues with the brand, citing concerns about pricing, portion sizes, and competition in the fast-casual dining sector.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

GOOGL is trending as investors anticipate earnings, with community members pointing to the stock's recent strength and potential AI-driven growth. Discussions include Google's partnership with Reliance Jio in India and its increased capital expenditure outlook, with some expecting the stock to test the $300 level. Bullish sentiment is fueled by positive analyst ratings and expectations of a strong quarter.

Alphabet Inc - Ordinary Shares - Class C

GOOG is trending as it approaches earnings, fueled by optimism around its AI and cloud services. The community is actively discussing the stock's impressive run and debating whether it's overbought, while also noting Google's expansion into new sectors like nuclear energy.

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. The Commercial Product Sales segment includes NARCAN products and other commercial products that were sold as part of the travel health business. The MCM Product Sales segment focuses on the Anthrax - MCM products, Smallpox - MCM products and other products. The Services segment consists of the company’s Bioservices offerings. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Emergent Biosolutions Inc

EBS is trending due to raised FY25 EBITDA guidance, sparking optimism about the company's future profitability. The community is discussing the potential for a significant stock re-rating and a short squeeze, with some highlighting the low P/E ratio relative to the broader market. Discussions also involve potential catalysts like government appropriations and debt refinancing.

Core Scientific, Inc. engages in the business of operating a purpose-built facility for digital asset mining and provision of blockchain infrastructure, software solutions, and services. It operates under the Mining and Hosting segments. The Mining segment focuses on bitcoin mining for the company's own account. The Hosting segment includes blockchain infrastructure and third-party hosting business. The company was founded by Michael Jeffrey Levitt and Darin Feinstein on December 13, 2017 and is headquartered in Dover, DE.

Core Scientific Inc - Ordinary Shares - New

Core Scientific Inc

Core Scientific ($CORZ) is trending as shareholders prepare to vote on a proposed merger with CoreWeave ($CRWV), with many in the community expressing concerns that the deal undervalues $CORZ, particularly given its AI infrastructure potential. Some investors believe that rejecting the deal could lead to a higher valuation for $CORZ as a standalone entity or attract a better offer, while others worry about the company's future prospects without the merger.

FMC Corp. is an agricultural sciences company, which engages in the provision of solutions to growers and development of pipeline in crop protection, plant health, agriculture, pest control, and turf management. It offers insect control products under the Rynaxypyr and Cyazypyr brands, herbicides under the Authority, Boral, Centium, Command, and Gamit brands, insecticides under the Talstar and Hero brands, flutriafol-based fungicides, and bionematicides under the Quartzo and Presence brands. The company was founded by John Bean in 1883 and is headquartered in Philadelphia, PA.

FMC Corp.

FMC Corp. is experiencing a significant drop, driven by a dividend cut and lowered full-year earnings expectations, prompting community concern about potential debt issues and bankruptcy. Despite the downturn, some investors view the stock as oversold, anticipating a turnaround as the company focuses on debt reduction. Community members are actively discussing entry points, potential rebound levels, and whether the steep decline is an overreaction.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Krystal Biotech's Heavy Reliance on Vyjuvek: Growth Driver or Risk Factor?

KRYS gains momentum with Vyjuvek's expanded FDA label and global approvals, while advancing a pipeline led by oncology candidate KB707.

Shares of Abeona Therapeutics Inc. (ABEO) were in the spotlight on Tuesday afternoon after it <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.abeonatherapeutics.com/press-releases/detail/303/u-s-fda-approves-zevaskyn-prademagene-zamikeracel">announced</a> that the U.S. Food and Drug Administration (FDA) has approved its gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa.Recessive dystrophic epidermolysis bullosa (RDEB) is a genetic skin disease with no known cure caused by a defect in the COL7A1 gene that leaves them unable to produce functioning type VII collagen.Patients with the disease have fragile skin characterized by extensive blistering and severe wounds that often cover more than 30% of the body surface. These wounds are difficult to heal, can remain open for years, and many that do close tend to reopen.Abeona stated that its ZEVASKYN sheet is the only FDA-approved product for treating RDEB wounds with a single application.ZEVASKYN consists of a patient’s skin cells that have been genetically modified to produce functional Type VII collagen. These sheets are then surgically applied to the patient’s wounded areas.Up to 12 credit card-sized sheets can be joined together to cover large areas in a single application, the company said.ZEVASKYN is expected to be available beginning in the third quarter of 2025 through ZEVASKYN Qualified Treatment Centers (QTCs), which are treatment centers located across the U.S. with experience in cell and gene therapy.However, H.C. Wainwright stated on Tuesday that it does not expect ZEVASKYN to have an immediate impact on Krystal Biotech’s Vyjuvek. Vyjuvek is a topical gel aimed at wound healing in patients with dystrophic epidermolysis bullosa.Vyjuvek remains the "differentiated opportunity, particularly with regard to cost, surface area coverage for wound healing and quality of life/convenience," the analyst told investors in a research note, as per TheFly.<a href="https://stocktwits.com/symbol/ABEO">ABEO stock</a> is down by about 16% this year but up by over 44% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/paypal-flags-uncertainty-in-global-macro-environment/chQ6JJNRbLW">PayPal Reports Better-Than-Expected Q1 Earnings But Flags Uncertainty In Global Macro Environment</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a medicine pill is seen in a hand dressed in a medical glove with the U.S. FDA logo in the background. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images) 

Abeona Therapeutics’ Gene Therapy Gets FDA Nod For Treating Rare Genetic Skin Disease

ZEVASKYN is expected to be available beginning in the third quarter of 2025 through ZEVASKYN Qualified Treatment Centers, located across the U.S. with experience in cell and gene therapy.

Equity

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeutics Inc. - ABEO

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeutics Inc. - ABEO SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of...

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Abeona Therapeutics Inc. (ABEO) on Behalf of Investors

Glancy Prongay & Murray LLP (GPM), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Abeona Therapeutics Inc. (Abeona or the Company...

The Law Offices of Frank R. Cruz Announces Investigation of Abeona Therapeutics Inc. (ABEO) on Behalf of Investors

The Law Offices of Frank R. Cruz announces an investigation of Abeona Therapeutics Inc. (Abeona or the Company) (NASDAQ: ABEO) on behalf of investors concerning the Companys possible violations of...

Abeona Therapeutics announces employee inducement grants

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.

Abeona Therapeutics Inc

Will Amazon.com ($AMZN) beat quarterly earnings? 
 
*Powered by Polymarket

Free shipping on millions of items. Get the best of Shopping and Entertainment with Prime. Enjoy low prices and great deals on the largest selection of everyday essentials and other products, including fashion, home, beauty, electronics, Alexa Devices, sporting goods, toys, automotive, pets, baby, books, video games, musical instruments, office supplies, and more.

Current Price	$5.14
Prev Close	$4.99
Open	$5.01
Dividend Yield	0.00%
50-Day Moving Average	$5.93
Beta	0.71
Avg. Volume	943,425.29
PE Ratio	7.91

52-Week High	$7.54
52-Week Low	$3.93
Market Capitalization	$255.88M
EPS (Annual)	-$1.55
Price to Book	1.56
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

ABEO
Abeona Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ABEO News

ABEOAbeona Therapeutics Inc